Rhythm Pharmaceuticals

RYTM

Market cap $7.38B

This biotech stock has gained around 80% so far this year. It has formed a new base.

Three of the five stocks to watch are part of the artificial intelligence trade, including chip company Nvidia.

Rhythm Pharmaceuticals, Inc. - Special Call Company Participants David Connolly - Head of Investor Relations & Corporate Communications David Meeker - Chairman, President & CEO Jennifer Chien - Executive VP & Head of North America Conference Call Participants Lewis Blevins Ashley Shoemaker Jonathan Wolleben - Citizens JMP Securities, LLC, Research Division Seamus Fernandez - Guggenheim Securities, LLC, Research Division Corinne Jenkins - Goldman Sachs Group, Inc., Research Division Kris Jenner - Rock Springs Capital Management LP Derek Archila - Wells Fargo Securities, LLC, Research Division Faisal Khurshid - Leerink Partners LLC, Research Division Ellen Horste - TD Cowen, Research Division Conversation David Connolly Head of Investor Relations & Corporate Communications Good morning, everybody. Thank you for joining us today.

While oncology is the largest therapeutic area in the pharmaceutical industry by revenue, the anti-obesity space has grabbed the most attention over the past couple of years. This niche is still in its infancy, though, and it is projected to grow rapidly at least through the end of the decade.

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 11:30 AM EDT Company Participants David Meeker - Chairman, President & CEO Conference Call Participants Michael Ulz - Morgan Stanley, Research Division Presentation Michael Ulz Equity Analyst All right. Good afternoon, everyone, and thanks for joining us at the Morgan Stanley Global Healthcare Conference.

BOSTON, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that David Meeker, M.D., Chair, President and Chief Executive Officer, will participate in fireside chats at two upcoming investor conferences:

– U.S. Food and Drug Administration accepts sNDA for filing with priority review; sets PDUFA goal date of December 20, 2025 -- – European Medicines Agency accepts and validates submission for Type II variation MAA for setmelanotide to treat acquired hypothalamic obesity –

Rhythm Pharmaceuticals (RYTM -1.85%), a biopharmaceutical company focused on rare genetic diseases related to obesity, reported its Q2 2025 earnings on August 5, 2025. However, the company reported a GAAP net loss per share of ($0.75).

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM ) Q2 2025 Earnings Conference Call August 5, 2025 8:00 AM ET Company Participants David Connolly - Head of Investor Relations & Corporate Communications David P. Meeker - Chairman, President & CEO Hunter C.

Rhythm Pharmaceuticals, Inc. (RYTM) came out with a quarterly loss of $0.75 per share versus the Zacks Consensus Estimate of a loss of $0.66. This compares to a loss of $0.55 per share a year ago.